HC Wainwright & Co. Reiterates Buy on Eledon Pharma, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino reiterated a Buy rating on Eledon Pharma (NASDAQ:ELDN) and maintained a $25 price target.
May 26, 2023 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Vernon Bernardino reiterated a Buy rating on Eledon Pharma and maintained a $25 price target.
The reiteration of a Buy rating and maintenance of a $25 price target by HC Wainwright & Co. analyst Vernon Bernardino indicates a positive outlook for Eledon Pharma. This news is likely to have a positive short-term impact on ELDN's stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100